NeogenFRA:NG2 +5.08%68 EBITDA Margin % is 10.66% as of Feb. 2026, which is 48% below its 10-year median of 20.57. GuruFocus rates FRA:NG2 with a GF Score™ of 68/100 and a GF Value™ of €10.73 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 813 Medical Devices & Instruments companies, Neogen ranks worse than 78.72% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Neogen's EBITDA for the
three
months ended in Feb. 2026 was €19.1 Mil. Neogen's Revenue for the
three
months ended in Feb. 2026 was €178.7 Mil. Therefore, Neogen's EBITDA margin for the quarter that ended in Feb. 2026 was 10.66%.
Neogen (FRA:NG2) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Neogen EBITDA Margin % Related Terms
Neogen EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Neogen's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:NG2 vs UFPT, ALMR, BFLY: EBITDA Margin % Comparison
For the Medical Devices subindustry, Neogen's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neogen EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Neogen's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Neogen's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neogen (FRA:NG2) has a EBITDA Margin % of 10.66% as of Feb. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Neogen and its competitors. This is 48% below median its historical median of 20.57. According to the industry distribution chart, Neogen ranks #640 out of 813 companies in the Medical Devices & Instruments industry, placing it in the top 78.7%.
Is Neogen's EBITDA Margin % too high?
Neogen's current EBITDA Margin % of 10.66% is 48% below median its 10-year median of 20.57. The Medical Devices & Instruments industry median EBITDA Margin % is 7.47. Neogen's value of 10.66% is 42.7% above this industry median. Based on the distribution chart, Neogen ranks #640 out of 813 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Neogen has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Neogen's EBITDA Margin % compare to UFPT and ALMR?
According to the Medical Devices & Instruments industry distribution chart, Neogen ranks #640 out of 813 companies for EBITDA Margin %. This places Neogen in the lower half of its industry. The industry median EBITDA Margin % is 7.47. Neogen's value of 10.66% is 42.7% above this benchmark. While the company's 10-year median is 20.57 vs. the industry median of 7.47, Neogen has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.47, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neogen's current EBITDA Margin % of 10.66% is 42.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Neogen and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neogen's current EBITDA Margin % is 10.66%, which is 48% below median its own 10-year median of 20.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neogen stock overvalued right now?
Based on GuruFocus' analysis, Neogen (FRA:NG2) is currently considered Modestly Undervalued. The stock's GF Value™ is €10.73, compared to a current price of €8.40 — trading 21.8% below its estimated fair value. The current EBITDA Margin % is 10.66%, which is 48% below median its 10-year median of 20.57 and 42.7% above the Medical Devices & Instruments industry median of 7.47. Neogen's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Neogen (FRA:NG2), the current EBITDA Margin % is 10.66% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neogen (FRA:NG2) Overvalued in 2026?
Based on GuruFocus' analysis, Neogen stock appears to be undervalued.
The current stock price of €8.40 is trading 21.8% below its estimated GF Value™ of €10.73.
GuruFocus considers Neogen to be Modestly Undervalued.
Key valuation signals for FRA:NG2:
EBITDA Margin %: 10.66% (48% below median its 10-year median of 20.57)
GF Value™: €10.73 vs. price of €8.40 (21.8% below fair value)
Industry Position: 42.7% above the Medical Devices & Instruments median (#640 of 813)
No single metric tells the full story. See the FRA:NG2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, the company performs diagnostics to detect unintended substances in food and animal feed, to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. In animal safety, the company segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products and genomics testing services.
68GF Score
Get the complete analysis for FRA:NG2
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:NG2 has been successfully added to your 
